BRPI0921685A2 - composição tópica compreendendo uma combinação de pelo menos dois agentes que melhoram a penetração. - Google Patents

composição tópica compreendendo uma combinação de pelo menos dois agentes que melhoram a penetração.

Info

Publication number
BRPI0921685A2
BRPI0921685A2 BRPI0921685A BRPI0921685A BRPI0921685A2 BR PI0921685 A2 BRPI0921685 A2 BR PI0921685A2 BR PI0921685 A BRPI0921685 A BR PI0921685A BR PI0921685 A BRPI0921685 A BR PI0921685A BR PI0921685 A2 BRPI0921685 A2 BR PI0921685A2
Authority
BR
Brazil
Prior art keywords
combination
topical composition
enhancing agents
penetration enhancing
penetration
Prior art date
Application number
BRPI0921685A
Other languages
English (en)
Inventor
Borgström Johan
Holmberg Anna
Lindahl Ake
Palsson Christian
Svensson Birgitta
Thelin Bernt
Den Bussche Van Helena
Original Assignee
Moberg Derma Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Moberg Derma Ab filed Critical Moberg Derma Ab
Publication of BRPI0921685A2 publication Critical patent/BRPI0921685A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
BRPI0921685A 2008-10-31 2009-10-29 composição tópica compreendendo uma combinação de pelo menos dois agentes que melhoram a penetração. BRPI0921685A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10997608P 2008-10-31 2008-10-31
PCT/SE2009/051230 WO2010050889A1 (en) 2008-10-31 2009-10-29 Topical composition comprising a combination of at least two penetration enhancing agents

Publications (1)

Publication Number Publication Date
BRPI0921685A2 true BRPI0921685A2 (pt) 2016-02-16

Family

ID=42129060

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0921685A BRPI0921685A2 (pt) 2008-10-31 2009-10-29 composição tópica compreendendo uma combinação de pelo menos dois agentes que melhoram a penetração.

Country Status (11)

Country Link
US (2) US20110207765A1 (pt)
EP (1) EP2340043A4 (pt)
JP (1) JP2012507511A (pt)
KR (1) KR20110090892A (pt)
CN (1) CN102196821A (pt)
AU (1) AU2009310437A1 (pt)
BR (1) BRPI0921685A2 (pt)
CA (1) CA2738970A1 (pt)
MX (1) MX2011004454A (pt)
RU (1) RU2011111206A (pt)
WO (1) WO2010050889A1 (pt)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL152486A0 (en) 2002-10-25 2003-05-29 Meir Eini Alcohol-free cosmetic and pharmaceutical foam carrier
US9265725B2 (en) 2002-10-25 2016-02-23 Foamix Pharmaceuticals Ltd. Dicarboxylic acid foamable vehicle and pharmaceutical compositions thereof
US10117812B2 (en) 2002-10-25 2018-11-06 Foamix Pharmaceuticals Ltd. Foamable composition combining a polar solvent and a hydrophobic carrier
US8636982B2 (en) 2007-08-07 2014-01-28 Foamix Ltd. Wax foamable vehicle and pharmaceutical compositions thereof
WO2009072007A2 (en) 2007-12-07 2009-06-11 Foamix Ltd. Carriers, formulations, methods for formulating unstable active agents for external application and uses thereof
US20100160368A1 (en) 2008-08-18 2010-06-24 Gregory Jefferson J Methods of Treating Dermatological Disorders and Inducing Interferon Biosynthesis With Shorter Durations of Imiquimod Therapy
EP2378876B1 (en) 2008-12-19 2018-11-14 Medicis Pharmaceutical Corporation Lower dosage strength imiquimod formulations and short dosing regimens for treating actinic keratosis
US20120087872A1 (en) 2009-04-28 2012-04-12 Foamix Ltd. Foamable Vehicles and Pharmaceutical Compositions Comprising Aprotic Polar Solvents and Uses Thereof
PL2453747T3 (pl) 2009-07-13 2018-02-28 Medicis Pharmaceutical Corporation Preparaty imikwimodu o niższej mocy dawki i krótkie schematy dawkowania do leczenia brodawek narządów płciowych i okolic odbytu
PT2387391T (pt) 2009-07-24 2017-04-20 Mika Pharma Ges Für Die Entw Und Vermarktung Pharmazeutischer Produkte Mbh Processo para o desenvolvimento de uma composição líquida a ser aplicada na forma de espuma sobre a pele e composição de aplicação tópica
WO2011013009A2 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surfactant hydro-alcoholic foamable compositions, breakable foams and their uses
CA2769677A1 (en) 2009-07-29 2011-02-03 Foamix Ltd. Non surface active agent non polymeric agent hydro-alcoholic foamable compositions, breakable foams and their uses
AU2010302350B2 (en) 2009-10-02 2015-06-18 Journey Medical Corporation Surfactant-free water-free foamable compositions, breakable foams and gels and their uses
US9849142B2 (en) 2009-10-02 2017-12-26 Foamix Pharmaceuticals Ltd. Methods for accelerated return of skin integrity and for the treatment of impetigo
US12661407B2 (en) 2010-04-08 2026-06-23 Journey Medical Corporation Compositions, gels and foams with rheology modulators and uses thereof
US20130309215A1 (en) * 2012-05-15 2013-11-21 Mika Pharma Gesellschaft Fur Die Entwicklung Und Vermarktung Pharmazeutischer Produkte Mbh Pharmaceutical composition
US8853189B2 (en) 2012-05-31 2014-10-07 Prima Innovations, Llc Antispasmodic 1,2-Diols and 1,2,3-triols
EP3409291A4 (en) * 2016-01-29 2019-09-18 Nissan Chemical Corporation TRANSDERMAL ABSORBABLE COMPOSITION WITH CONTROLLED RELEASE OF A WATER SOLUBLE ACTIVE ACTIVE SUBSTANCE
US10258560B1 (en) 2016-08-08 2019-04-16 Marlinz Pharma, LLC Composition for topical treatment of nail conditions
US10543276B2 (en) 2016-08-08 2020-01-28 Marlinz Pharma, LLC Topical compositions
MX2020012139A (es) 2016-09-08 2021-01-29 Vyne Pharmaceuticals Inc Composiciones y metodos para tratar rosacea y acne.
MX386903B (es) * 2016-10-21 2025-03-19 Crescita Therapeutics Inc Composiciones farmacéuticas tópicas y uso en el tratamiento de afecciones cutáneas.
EP3801460B1 (en) 2018-06-01 2025-03-12 Tavanta Therapeutics Hungary Incorporated Topical amlodipine salts for the treatment of anorectal diseases
EP4252844A3 (en) * 2019-04-17 2023-12-06 Azora Therapeutics, Inc. Topical compositions and methods for treating inflammatory skin diseases
CN119184033A (zh) * 2024-11-14 2024-12-27 广州华珍生物科技有限公司 一种银屑病动物模型的构建方法及其应用

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4552872A (en) * 1983-06-21 1985-11-12 The Procter & Gamble Company Penetrating topical pharmaceutical compositions containing corticosteroids
US4590190A (en) * 1983-07-01 1986-05-20 Nitto Electric Industrial Co., Ltd. Method for percutaneously administering physiologically active agents using an alcohol adjuvant and a solvent
JPS6016917A (ja) * 1983-07-08 1985-01-28 Yamanouchi Pharmaceut Co Ltd 塩酸ニカルジピンまたはニフエジピンの軟膏剤
US6005001A (en) * 1991-05-20 1999-12-21 Novartis Ag (Formerly Sandoz Ag) Pharmaceutical composition
HU223343B1 (hu) * 1991-05-20 2004-06-28 Novartis Ag. Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
DE4210165A1 (de) * 1991-07-30 1993-02-04 Schering Ag Transdermale therapeutische systeme
US5238933A (en) * 1991-10-28 1993-08-24 Sri International Skin permeation enhancer compositions
GB9404248D0 (en) * 1994-03-05 1994-04-20 Boots Co Plc Pharmaceutical formulations
SE9601665D0 (sv) * 1996-04-30 1996-04-30 Bioglan Ab Biologically active composition
US5837289A (en) * 1996-07-23 1998-11-17 Grasela; John C. Transdermal delivery of medications using a combination of penetration enhancers
US5760096A (en) * 1996-10-18 1998-06-02 Thornfeldt; Carl R. Potent penetration enhancers
CA2309688C (en) * 1997-11-10 2007-04-24 Cellegy Pharmaceuticals, Inc. Penetration enhancing and irritation reducing systems
US10179159B2 (en) * 1999-10-22 2019-01-15 Scott Wepfer Topical anesthetic formulation
US20030139384A1 (en) * 2000-08-30 2003-07-24 Dudley Robert E. Method for treating erectile dysfunction and increasing libido in men
US20040092494A9 (en) * 2000-08-30 2004-05-13 Dudley Robert E. Method of increasing testosterone and related steroid concentrations in women
US6503894B1 (en) * 2000-08-30 2003-01-07 Unimed Pharmaceuticals, Inc. Pharmaceutical composition and method for treating hypogonadism
IL161786A0 (en) * 2001-11-29 2005-11-20 3M Innovative Properties Co Pharmaceutical formulations comprising an immune
EP1667694B1 (en) * 2003-09-05 2010-04-28 Anadys Pharmaceuticals, Inc. Tlr7 ligands for the treatment of hepatitis c
US7425340B2 (en) * 2004-05-07 2008-09-16 Antares Pharma Ipl Ag Permeation enhancing compositions for anticholinergic agents
CA2573412A1 (en) * 2004-07-19 2006-02-02 Warner-Lambert Company Llc Formulation for stimulating hair growth
EP1634583A1 (en) * 2004-09-09 2006-03-15 Laboratoires Besins International Testosterone gels comprising propylene glycol as penetration enhancer
US20070179121A1 (en) * 2006-02-02 2007-08-02 Plott R T Method of treating pediatric patients with corticosteroids
US9023863B2 (en) * 2006-07-14 2015-05-05 Stiefel Research Australia Pty Ltd Fatty acid pharmaceutical foam
US20080260655A1 (en) * 2006-11-14 2008-10-23 Dov Tamarkin Substantially non-aqueous foamable petrolatum based pharmaceutical and cosmetic compositions and their uses
PE20081406A1 (es) * 2006-12-20 2008-10-17 Schering Plough Ltd Composiciones farmaceuticas de flunixina

Also Published As

Publication number Publication date
RU2011111206A (ru) 2012-12-10
MX2011004454A (es) 2011-08-15
WO2010050889A1 (en) 2010-05-06
US20130202650A1 (en) 2013-08-08
KR20110090892A (ko) 2011-08-10
EP2340043A4 (en) 2012-09-19
CN102196821A (zh) 2011-09-21
CA2738970A1 (en) 2010-05-06
EP2340043A1 (en) 2011-07-06
AU2009310437A1 (en) 2010-05-06
JP2012507511A (ja) 2012-03-29
US20110207765A1 (en) 2011-08-25

Similar Documents

Publication Publication Date Title
EP2261309A4 (en) LUBRICANT COMPOSITION
EP2319908A4 (en) LUBRICANT COMPOSITION
EP2251402A4 (en) LUBRICANT COMPOSITION
EP2381760A4 (en) CORN PROTEIN COMPOSITION
BRPI0919155A2 (pt) composição aquosa injetável
BRPI0915731A2 (pt) composição de graxa.
BRPI0906749A2 (pt) Composição
BRPI0913808A2 (pt) composição
EP2316912A4 (en) GREASE COMPOSITION
BRPI0814010A2 (pt) Composição de aço
BRPI0915732A2 (pt) composição de graxa.
EP2053117A4 (en) LUBRICANT COMPOSITION
EP2340043A4 (en) TOPICAL COMPOSITION COMPRISING A COMBINATION OF AT LEAST TWO PENETRATION AGENTS
BRPI0906607A2 (pt) Agentes de coalescência eficazes.
IT1392101B1 (it) Composizione comprendente isoflavoni
BRPI0716325A2 (pt) Composição antimicrobianas
EP2221325A4 (en) Photochromic curable composition
BRPI0917231A2 (pt) composição
EP2223992A4 (en) LUBRICANT COMPOSITION
EP2141220A4 (en) LUBRICANT COMPOSITIONS
EP2119761A4 (en) LUBRICANT COMPOSITION
EP2003187A4 (en) LUBRICANT COMPOSITIONS
BRPI0905369A2 (pt) Composição farmacêutica, composição e kit compartimentado
BRPI0923490A2 (pt) composição de vedação hidraulicamente configurada
EP1985195A4 (en) SHOE

Legal Events

Date Code Title Description
B08F Application fees: application dismissed [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 5A, 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2384 DE 13-09-2016 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.